$1.02 Billion is the total value of BVF INC/IL's 51 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 125.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MRUS | Buy | MERUS N V | $89,103,000 | +98.7% | 3,914,913 | +61.8% | 8.70% | +91.3% |
| KURA | Buy | KURA ONCOLOGY INC | $37,444,000 | +47.5% | 2,057,346 | +52.0% | 3.65% | +42.0% |
| MRTX | New | MIRATI THERAPEUTICS INC | $36,729,000 | – | 745,000 | +100.0% | 3.58% | – |
| INFI | Buy | INFINITY PHARMACEUTICALS INC | $29,094,000 | +41.9% | 15,232,268 | +56.0% | 2.84% | +36.6% |
| PIRS | Buy | PIERIS PHARMACEUTICALS INC | $27,108,000 | +10.6% | 5,346,838 | +48.8% | 2.65% | +6.5% |
| IONS | New | IONIS PHARMACEUTICALS INC | $23,752,000 | – | 570,000 | +100.0% | 2.32% | – |
| FWP | Buy | FORWARD PHARMA A/Ssponsored adr | $23,129,000 | +124.1% | 8,503,425 | +78.8% | 2.26% | +115.8% |
| GLMD | New | GALMED PHARMACEUTICALS LTD | $20,963,000 | – | 1,761,567 | +100.0% | 2.05% | – |
| IMDZ | Buy | IMMUNE DESIGN CORP | $18,921,000 | +39.6% | 4,158,353 | +1.3% | 1.85% | +34.4% |
| FPRX | New | FIVE PRIME THERAPEUTICS INC | $17,862,000 | – | 1,129,761 | +100.0% | 1.74% | – |
| MEIP | New | MEI PHARMA INC | $12,136,000 | – | 3,080,308 | +100.0% | 1.18% | – |
| CDTX | New | CIDARA THERAPEUTICS INC | $10,039,000 | – | 1,930,670 | +100.0% | 0.98% | – |
| PTGX | Buy | PROTAGONIST THERAPEUTICS INC | $9,529,000 | +173.5% | 1,417,967 | +249.6% | 0.93% | +163.5% |
| SURF | New | SURFACE ONCOLOGY INC | $5,453,000 | – | 334,333 | +100.0% | 0.53% | – |
| MACK | New | MERRIMACK PHARMACEUTICALS INC | $5,453,000 | – | 1,110,588 | +100.0% | 0.53% | – |
| GNCA | Buy | GENOCEA BIOSCIENCES INC | $4,505,000 | -14.2% | 5,265,000 | +5.3% | 0.44% | -17.3% |
| EPIX | New | ESSA PHARMA INC | $2,090,000 | – | 552,791 | +100.0% | 0.20% | – |
| ZYME | New | ZYMEWORKS INC | $293,000 | – | 19,804 | +100.0% | 0.03% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 36 | Q3 2023 | 4.7% |
| PIERIS PHARMACEUTICALS INC | 30 | Q3 2023 | 2.8% |
| CYTOKINETICS INC | 29 | Q4 2020 | 11.8% |
| INFINITY PHARMACEUTICALS INC | 29 | Q2 2023 | 4.3% |
| XOMA CORP DEL | 28 | Q3 2023 | 7.3% |
| ARQULE INC | 27 | Q4 2019 | 4.8% |
| CHEMOCENTRYX INC | 26 | Q3 2019 | 13.8% |
| CYTOMX THERAPEUTICS INC | 26 | Q3 2023 | 5.3% |
| CORVUS PHARMACEUTICALS INC | 26 | Q3 2023 | 2.3% |
| ARRAY BIOPHARMA INC | 25 | Q2 2019 | 14.5% |
View BVF INC/IL's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-13 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-01-29 |
| 3 | 2024-01-26 |
| 4 | 2024-01-09 |
| 4 | 2023-12-20 |
| 4 | 2023-11-17 |
| 13F-HR | 2023-11-14 |
| 3 | 2023-11-13 |
View BVF INC/IL's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.